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Abstract
IMPORTANCE The presence of atrophy on magnetic resonance imaging can support the diagnosis
of the behavioral variant of frontotemporal dementia (bvFTD), but reproducible measurements
are lacking.
OBJECTIVE To assess the diagnostic and prognostic utility of 6 visual atrophy scales (VAS) and the
Magnetic Resonance Parkinsonism Index (MRPI).
DESIGN, SETTING, AND PARTICIPANTS In this diagnostic/prognostic study, data from 235 patients
with bvFTD and 225 age- and magnetic resonance imaging–matched control individuals from 3
centers were collected from December 1, 1998, to September 30, 2019. One hundred twenty-one
participants with bvFTD had high confidence of frontotemporal lobar degeneration (FTLD)
(bvFTD-HC), and 19 had low confidence of FTLD (bvFTD-LC). Blinded clinicians applied 6 previously
validated VAS, and the MRPI was calculated with a fully automated approach. Cortical thickness and
subcortical volumes were also measured for comparison. Data were analyzed from February 1 to June
30, 2020.
MAIN OUTCOMES AND MEASURES The main outcomes of this study were bvFTD-HC or a
neuropathological diagnosis of 4-repeat (4R) tauopathy and the clinical deterioration rate (assessed
by longitudinal measurements of Clinical Dementia Rating Sum of Boxes). Measures of cerebral
atrophy included VAS scores, the bvFTD atrophy score (sum of VAS scores in orbitofrontal, anterior
cingulate, anterior temporal, medial temporal lobe, and frontal insula regions), the MRPI, and other
computerized quantifications of cortical and subcortical volumes. The areas under the receiver
operating characteristic curve (AUROC) were calculated for the differentiation of participants with
bvFTD-HC and bvFTD-LC and controls. Linear mixed models were used to evaluate the ability of
atrophy measures to estimate longitudinal clinical deterioration.
RESULTS Of the 460 included participants, 296 (64.3%) were men, and the mean (SD) age was
62.6 (11.4) years. The accuracy of the bvFTD atrophy score for the differentiation of bvFTD-HC from
controls (AUROC, 0.930; 95% CI, 0.903-0.957) and bvFTD-HC from bvFTD-LC (AUROC, 0.880;
95% CI, 0.787-0.972) was comparable to computerized measures (AUROC, 0.973 [95% CI, 0.954-
0.993] and 0.898 [95% CI, 0.834-0.962], respectively). The MRPI was increased in patients with
bvFTD and underlying 4R tauopathies compared with other FTLD subtypes (14.1 [2.0] vs 11.2 [2.6]
points; P < .001). Higher bvFTD atrophy scores were associated with faster clinical deterioration in
bvFTD (1.86-point change in Clinical Dementia Rating Sum of Boxes score per bvFTD atrophy score
increase per year; 95% CI, 0.99-2.73; P < .001).
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Abstract (continued)
CONCLUSIONS AND RELEVANCE Based on these study findings, in bvFTD, VAS increased the
diagnostic certainty of underlying FTLD, and the MRPI showed potential for the detection of
participants with underlying 4R tauopathies. These widely available measures of atrophy can also be
useful to estimate longitudinal clinical deterioration.
JAMA Network Open. 2021;4(3):e211290. doi:10.1001/jamanetworkopen.2021.1290
Introduction
The behavioral variant of frontotemporal dementia (bvFTD) is the leading clinical presentation of
frontotemporal lobar degeneration (FTLD).1 According to bvFTD diagnostic criteria, the presence of
frontal or anterior temporal cerebral atrophy on magnetic resonance imaging (MRI) can be used to
increase diagnostic certainty of underlying FTLD, and longitudinal studies have shown that cortical
atrophy is associated with a faster clinical deterioration.2-4 However, objective and reproducible
measurements of atrophy are lacking, and the specific value of MRI measures for differentiating
between cases with nonneurodegenerative bvFTD and those with underlying FTLD is unclear.5
Previous studies applied sophisticated data-driven approaches to characterize atrophy, but these
methods may be difficult to replicate across centers.6,7 On the contrary, visual atrophy scales (VAS)
represent accessible and reliable measures of cerebral atrophy.8
An additional challenge is that bvFTD is associated with multiple FTLD subtypes, some of which
are characterized by subcortical atrophy at diagnosis (eg, bvFTD with underlying progressive
supranuclear palsy [PSP] or corticobasal degeneration [CBD]).9 The Magnetic Resonance
Parkinsonism Index (MRPI) allows for the quantification of the relative volume loss in the midbrain
and superior cerebellar peduncle and has shown excellent performance for the diagnosis of PSP, even
before the emergence of canonical motor symptoms.10
In this multicenter study, we explored the clinical value of 6 VAS and the MRPI for differentiating
between participants with bvFTD with high and low confidence of FTLD and healthy control
individuals. We also examined the role of these accessible measures of atrophy for estimating
underlying pathology and clinical deterioration rate.
Methods
Participant Selection
Figure 1 shows a flowchart of the sample composition for this diagnostic/prognostic study. Inclusion
criteria for bvFTD participants were (1) meeting the International Behavioral Variant FTD Criteria
Consortium revised guidelines for the diagnosis of at least possible bvFTD2 and (2) having MRI
findings available for analysis at the time of diagnosis. Participants were recruited at 3 different
centers: 160 at the University of California, San Francisco, Memory and Aging Center, 59 at Hospital
de Sant Pau, Barcelona, Spain, and 16 at the Hospital Clinic, Barcelona, Spain. All patients underwent
a complete clinical history, physical examination, neuropsychological evaluation, and structural brain
imaging. A total of 225 age-matched healthy participants were also included as imaging controls. All
controls had normal cognitive performance according to local normative data11 and did not have any
neurological, psychiatric, or other major medical illnesses. This study followed the Strengthening the
Reporting of Observational Studies in Epidemiology (STROBE) reporting guideline. The study was
approved by the institutional review board of each center and was conducted following the
Declaration of Helsinki. Written informed consent was obtained from all participants.
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Clinical Evaluation and Detailed Behavioral Assessment
Data were collected from December 1, 1998, through September 30, 2019. At presentation, the
following measures of clinical deterioration were recorded: the Clinical Dementia Rating (CDR), the
CDR Sum of Boxes (CDR-SOB),12 the Mini-Mental State Examination (MMSE),13 and the frequency-by-
severity and scores of Neuropsychiatric Inventory.14 During follow-up of participants with bvFTD, the
clinical features were reviewed, and we recorded additional measurements of MMSE (227 at
baseline, 92 at year 1, and 45 at year 2) and CDR-SOB (199 at baseline, 86 at year 1, and 35 at year 2).
The development of any additional syndromes, including amyotrophic lateral sclerosis,
PSP–Richardson syndrome (PSP-RS), and semantic variant primary progressive aphasia, was also
registered.15-18
Classification of bvFTD Participants
Participants with bvFTD were classified in 3 groups based on the certainty of underlying FTLD. In the
first group, we included participants with bvFTD with high confidence of FTLD (bvFTD-HC). This
group was composed of 68 participants with autopsy-confirmed FTLD (including 24 FTLD mutations
[15 C9orf72, 6 GRN, and 3 MAPT] and 7 with a second FTD-spectrum syndrome developed during
follow-up [2 amyotrophic lateral sclerosis, 2 PSP-RS, and 3 semantic variant primary progressive
aphasia]),9,19 48 with FTLD-related mutations,9,11 and 36 who developed a second FTD-spectrum
syndrome during follow-up (22 with amyotrophic lateral sclerosis,15 10 with PSP-RS,16 and 4 with
semantic variant primary progressive aphasia17). In the second group, we included 19 participants
with bvFTD with low confidence of FTLD (bvFTD-LC). This group included 13 participants who
received an alternative, non–FTD-spectrum syndromic diagnosis during follow-up and 6 in whom
FTLD was ruled out on autopsy results (eTable 1 in the Supplement). Of note, the bvFTD-LC group
included participants verifying bvFTD criteria at diagnosis but without clinical deterioration or
alternative psychiatric diagnosis during follow-up (bvFTD phenocopies). Of note, all participants
included in the bvFTD-LC group had negative test results for the C9orf72 expansion. In the third
group, we included the remainder of the participants with bvFTD with intermediate confidence of
FTLD (bvFTD-IC) (n = 95).
Structural MRI Acquisition
The images were acquired on scanners from 7 different manufacturers using different imaging
protocols (eTable 2 in the Supplement). Magnetic field strength varied at 1.5 T (48 scans), 3.0 T (385
scans), and 4.0 T (27 scans).
Figure 1. Flowchart of the Sample Composition
327 Excluded
184 Without MRI at diagnosis
126 Without information on
diagnostic criteria
17 With poor quality MRI
562 Patients diagnosed with
bvFTD at first visit
95 Participants with intermediate
confidence of FTLD
121 Participants with high
confidence of FTLD
19 Participants with low
confidence of FTLD














bvFTD indicates behavioral variant of frontotemporal dementia; CATFI, Catalan Frontotemporal Dementia Initiative; FTLD, frontotemporal lobar degeneration; MRI, magnetic
resonance imaging; and UCSF, University of California, San Francisco.
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Rating of Cerebral Atrophy With VAS
Six neurologists (I.I.-G., N.F., A.F., S.C.-S., O.K., and N.R.) blinded to any clinical information applied 6
VAS in all participants. These previously published VAS were optimized to improve their usability and
consistency (eg, precise slice selection for rating), validated in a large postmortem study by Harper
et al,8 and included a 5-point anterior temporal scale,20,21 a 5-point medial temporal lobe atrophy
scale,22 a 4-point posterior atrophy scale,23 a 4-point orbitofrontal scale,8 a 4-point anterior cingulate
scale,8 and a 4-point frontoinsula scale.8 The application of these VAS takes a mean of less than 3
minutes per participant.8 All raters first received a 1-hour training session. After this training session,
all raters applied the scale in an independent data set of 20 MRI scans (1 measurement for each
hemisphere, 40 measurements for each scale). Each evaluator received feedback on their
performance compared with other raters in this first training data set, and consistent disagreement
for each scale was discussed in a second meeting. Before the beginning of the study, all raters
assessed a second set of 20 participants included in the study to provide additional independent
validation of the results. We confirmed the reliability of VAS measurements in an independent data
set (eTable 3 in the Supplement). Images were rated in native space, in keeping with standard clinical
reads, and separate scores were recorded for regions in the left and right hemispheres. Also, to aid
rating consistency, all the raters were trained with the same instructions, slice selection, and
reference images as in the validation by Harper and collaborators.8 Left and right hemisphere scores
were added to provide a single measure of atrophy for each of the 6 regions (eTable 4 in the
Supplement). We also aimed to obtain a single measure of frontotemporal atrophy that could be
easily calculated by clinicians at the bedside to identify patients with bvFTD-HC: the bvFTD atrophy
score. To achieve this, we added the scores of 5 of the 6 VAS included in this study (anterior cingulate,
orbitofrontal, frontal insula, anterior temporal, and medial temporal lobe). The bvFTD atrophy score
can range from 0 to a maximum of 44 (22 per hemisphere), with higher scores indicating greater
levels of atrophy. Of note, the selection of these VAS for the calculation of the bvFTD atrophy score
was based in their ability to discriminate bvFTD with underlying FTLD from controls and other
dementias in a previous pathology-proven study.8
Cortical Thickness and Subcortical Grey Matter Volumes
The MRIs were processed with the CAT12 toolbox within SPM12 (running in MATLAB r2019b;
MathWorks) to obtain the mean cortical thickness in each region on the Desikan atlas and subcortical
gray matter volumes in the neuromorphometrics atlas.24,25 We then calculated the mean cortical
thickness at each region in the Desikan atlas and the volumes of subcortical gray matter structures in
the neuromorphometrics atlas, as implemented in CAT12. We also calculated the MRPI, which is
derived from midbrain and pons areas and middle and superior cerebellar peduncle widths following
a previously validated, fully automated method.26,27
Measures of Atrophy for the Diagnosis of bvFTD
We hypothesized that the bvFTD atrophy score would provide similar diagnostic accuracy for the
identification of bvFTD-HC to measures obtained by more sophisticated data-driven approaches. We
were particularly interested in comparing the diagnostic accuracy of the different atrophy measures
for the differentiation between bvFTD-HC and controls and between bvFTD-HC and bvFTD-LC. We
designed 2 different discriminant factor analyses (DFA; Wilks lambda and stepwise selection of
independents method) for the identification of bvFTD-HC in each of these 2 subsamples. We
performed additional DFA in other subsamples for other secondary analyses, including participants
classified in the bvFTD-IC group (eTable 5 in the Supplement). We then calculated the areas under
the receiver operating characteristic curve (AUROC) for all measures (atrophy measures and
estimated probabilities obtained from DFA models) in each subsample. We performed a secondary
analysis to explore whether MRPI could detect participants with bvFTD with high risk of underlying
PSP pathology by calculating the AUROC of MRPI to differentiate between participants with bvFTD
progressing to PSP-RS or pathology proven PSP-CBD and other FTLD cases. Finally, to determine
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whether the atrophy measures were significantly different from each other, we compared receiver
operating curves with a nonparametric test that accounts for the correlation of the curves.28 This test
takes advantage of the equality between the Mann-Whitney statistic for comparing distributions and
the AUROC when computed by the trapezoidal rule.
Measures of Atrophy for the Estimation of Clinical Deterioration
We aimed to compare the ability of the bvFTD atrophy score to estimate clinical deterioration with
other automated measures that capture FTLD-related atrophy at the single subject level. For doing
this, we first calculated the mean cortical thickness and subcortical gray matter volume for both
hemispheres for all the analyses, as in previous bvFTD studies (eTable 4 in the Supplement).7 Then,
we obtained the mean frontotemporal cortical thickness by calculating the mean cortical thickness of
all the frontal and temporal regions in the Desikan atlas. Because subcortical gray matter volumes
(but not cortical thickness) depend on total intracranial volume,29 we divided subcortical gray matter
volumes by total intracranial volume of each participant to obtain normalized subcortical volumes.
Comparison of Imaging Methods for Capturing Atrophy
To illustrate the ability of the bvFTD atrophy score to capture frontotemporal atrophy in participants
with bvFTD, we studied the correlation of cortical thickness with the bvFTD atrophy score in all
participants with bvFTD using multiple regressions with individual bvFTD atrophy scores as the
variable of interest and age, sex, and MRI scanner as covariates. We considered a significant statistical
threshold of 2-sided P < .05, corrected for false discovery rate, using an extent threshold of the
expected vertices per cluster. Finally, we compared the bvFTD-LC group (n = 19) and subgroups (ie,
no FTLD [n = 6] and psychiatric subgroups [n = 13]) with healthy controls following the same
approach. In these analyses, we set a less restrictive threshold for statistical significance of 2-sided
P < .001 to increase our sensitivity to capture small to moderate effect sizes owing to the relatively
small sample size of the bvFTD-LC group.
Clinical Deterioration Analyses of Participants With bvFTD
In longitudinal studies, linear mixed-effects have proven to be powerful tools for identifying variables
where baseline values are associated with different rates of changes in clinical deterioration.30 We
fitted linear mixed-effects analyses controlling for age, sex, genetic status (presence or absence of an
FTLD-related mutation), and different measures of atrophy (bvFTD atrophy score, MRPI,
frontotemporal cortical thickness, and subcortical gray matter volume) to estimate clinical
deterioration over time in participants with bvFTD, as measured by CDR-SOB. All models included a
random patient-specific intercept and a random patient-specific slope. These random effects
account for patient heterogeneity in baseline CDR-SOB and its rate of increase that is not explained
by the predictive factors in the model. A term for biomarker by time interaction was used to study the
association between the baseline biomarker level and CDR-SOB over time. As a secondary analysis,
we fitted additional linear mixed-effects models replacing CDR-SOB with MMSE (as an alternative
measure of general clinical deterioration in bvFTD).31 As in similar previous studies,32 all linear mixed
models were designed with a compound symmetry covariance structure (owing to the relative
homogeneity in the covariance of effects). Of note, we obtained essentially the same results when
linear mixed models were fitted with an unstructured covariance.
Other Statistical Analysis
Data were analyzed from February 1 to June 30, 2020. Data were explored for normality using the
Kolmogorov-Smirnov test. Between-group differences in baseline characteristics and measures of
atrophy were assessed using the 2-tailed unpaired t test, analysis of variance, Mann-Whitney test, or
Kruskal-Wallis test for continuous variables and the χ2 test for categorical data. We also performed
secondary analyses to compare MRPI levels among pathology-proven PSP-CBD, cases progressing to
PSP-RS, and other cases with FTLD. We applied the Spearman correlation index (ρ value) to study
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the correlation between measures of clinical deterioration and measures of cerebral atrophy with
bootstrapping-based 95% CIs (bias corrected and accelerated for 1000 samples). Statistical
significance for all tests was set at 5% (α = .05), and all statistical tests were 2 sided. All analyses were
performed using SPSS, version 25 (IBM Corp).
Results
Demographic and Clinical Characteristics of Participants
Among the 460 included participants (296 men [64.3%] and 164 women [35.7%]; mean [SD] age,
62.6 [11.4] years), age at MRI (mean [SD], 63.3 [10] vs 61.8 [12.6] years) and educational level (mean
[SD], 14.7 [4.4] vs 15.3 [3.8] years) were similar in the bvFTD and control groups (Table). Mean (SD)
age at symptom onset (range, 56.2 [10.3] to 59.5 [10.0] years), MMSE score (range, 22.7 [6.7] to 26.7
[2.6] years), and CDR-SOB score (range, 4.6 [1.9] to 7.4 [3.3]) were similar among bvFTD subgroups,
but mean (SD) follow-up time was higher in the bvFTD-LC group (2.3 [1.3] years) than in the bvFTD-IC
(1.2 [1.5] years) and bvFTD-HC (1.2 [1.3] years) groups. As shown in eFigure 1 in the Supplement, the
behavioral profile of bvFTD subgroups was similar, but the bvFTD-LC group had higher scores in the
Neuropsychiatric Inventory irritability domain (mean [SD], 6.3 [4.6]) than the bvFTD-IC (mean [SD],
3.3 [4.3]) and bvFTD-HC (mean [SD], 2.3 [3.1]) groups (P = .003).













Age at symptom onset, y 59.5 (10.0) 56.7 (10.8) 56.2 (10.3) 57.7 (10.5) NA
Age at MRI, y 64.9 (9.6) 62.1 (10.4) 63.4 (10.1) 63.3 (10) 61.8 (12.6)
No. (%) male 63 (66.3) 86 (71.1) 16 (84.2) 165 (70.2) 131 (58.2)b
Educational level, y 15.0 (4.2) 14.7 (4.4) 13.1 (4.9) 14.7 (4.4) 15.3 (3.8)
MMSE scorec 23.5 (6.6) 22.7 (6.7) 26.7 (2.6) 23.4 (6.5) 29.0 (1.1)b,d
CDR-SOB scoree 5.8 (3.4) 7.4 (3.3) 4.6 (1.9) 6.5 (3.4) 0 (0.1)b,d
Time of follow-up, y 1.2 (1.5) 1.2 (1.3) 2.3 (1.3)f 1.3 (1.4) NA
Cohort, No. CATFI/UCSF 28/67 39/82 8/11 75/160 57/168
VAS score
Orbitofrontal 2.9 (2.0) 3.0 (2.0) 0.8 (1.2)f 2.8 (2.0) 0.8 (1.1)b,g
Anterior cingulate 3.7 (1.7) 4.2 (1.6) 1.9 (1.8)f 3.8 (1.8) 1.6 (1.4)b,g
Anterior temporal 2.9 (1.5) 3.2 (1.6) 1.7 (0.9)f 3.0 (1.6) 1.6 (1.0)b,g
Medial temporal lobe 2.9 (2.3) 3.2 (2.1) 1.3 (1.9)f 2.9 (2.2) 0.6 (1.2)b,g
Frontal insula 3.1 (1.7) 3.4 (1.7) 1.0 (1.4)f 3.1 (1.8) 1.2 (1.2)b,g
Posterior atrophy 0.6 (1.0) 0.9 (1.1) 0.4 (0.7) 0.8 (1.1) 0.7 (1.0)
bvFTD atrophyh 15.7 (7.2) 16.9 (6.4) 6.7 (5.8)f 15.6 (7.2) 5.8 (4.0)b,g
MRPI
Midbrain volume, mm3 106.2 (20.4) 104.3 (21.1) 125.6 (20.2)f 106.8 (21.4) 128.0 (23.0)b,g
Pons volume, mm3 490.3 (57.7) 493.6 (60.0) 519.0 (54.9) 494.3 (54.4) 494.3 (52.7)
Superior cerebellar peduncle
width, mm
3.8 (0.4) 3.8 (0.4) 3.7 (0.5) 3.8 (0.4) 3.9 (0.4)b
Middle cerebellar peduncle
width, mm
8.8 (0.8) 8.9 (0.8) 9.1 (0.9) 8.9 (0.8) 9.1 (0.7)b,i
Midbrain to pons ratio 0.22 (0.04) 0.21 (0.04) 0.24 (0.04) 0.22 (0.04) 0.26 (0.05)






2.6 (0.2) 2.5 (0.2) 2.8 (0.2)f 2.6 (0.2) 2.9 (0.1)b,f
Subcortical gray matter
ratiok
1.3 (0.2) 1.2 (0.2) 1.4 (0.2)f 1.3 (0.2) 1.6 (0.2)b,d
Abbreviations: bvFTD, behavioral variant of
frontotemporal dementia; CATFI, Catalan
Frontotemporal Dementia Initiative; CDR-SOB, Clinical
Dementia Rating Sum of Boxes; HC, high confidence;
IC, intermediate confidence; LC, low confidence;
MMSE, Mini-Mental State Examination; MRPI,
Magnetic Resonance Parkinsonism Index; NA, not
applicable; UCSF, University of California, San
Francisco; VAS, visual atrophy scales.
a Unless otherwise indicated, data are expressed as
mean (SD).
b P < .05 compared with all-bvFTD group.
c Scores range from 0 to 30, with higher scores
indicating better cognition.
d P < .05 compared with bvFTD-IC, bvFTD-HC, and bvFTD-
LC groups.
e Scores range from 0 to 18, with higher scores
indicating more advanced dementia. This measure
was available for 199 participants with bvFTD
(84.7%) and 188 healthy controls (83.6%).
f P < .05 compared with bvFTD-IC and bvFTD-HC.
g P < .05 compared with bvFTD-HC and bvFTD-LC.
h The bvFTD atrophy score ranges from 0 to 34, with
higher scores indicating more cortical atrophy, as
measured with VAS. The bvFTD atrophy score results
from the addition of orbitofrontal, anterior cingulate,
anterior temporal, medial temporal lobe, and frontal
insula atrophy scores of both hemispheres.
i P < .05 compared with bvFTD-IC.
j Indicates mean of cortical thickness at frontal and
temporal regions of both hemispheres.
k Indicates mean of volumes of accumbens, amygdala,
caudate nucleus, hippocampus, putamen, and
thalamus of both hemispheres divided by the
resulting volume by total intracranial volume.
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Group Differences in Cerebral Measurements of Atrophy
Among the bvFTD-IC and bvFTD-HC groups, the mean (SD) VAS scores in orbitofrontal (2.9 [2.0] and
3.0 [2.0], respectively), anterior cingulate (3.7 [1.7] and 4.2 [1.6], respectively), medial temporal lobe
(2.9 [1.5] and 3.2 [1.6], respectively), and the frontal insula (3.1 [1.7] and 3.4 [1.7], respectively) regions
and the total bvFTD atrophy score (15.7 [7.2] and 16.9 [6.4], respectively) were higher compared with
bvFTD-LC (orbitofrontal, 0.8 [1.2]; anterior cingulate, 1.9 [1.8]; medial temporal, 1.3 [1.9]; frontal
insula, 1.0 [1.4]; and total atrophy, 6.7 [5.8]) and control (orbitofrontal, 0.8 [1.1]; anterior cingulate,
1.67 [1.4]; medial temporal, 06 [1.2]; frontal insula, 1.2 [1.2]; and total atrophy, 5.8 [4.0]) groups (Table
and Figure 2A). Of note, the bvFTD atrophy score showed an excellent correlation with cortical
thickness in frontotemporal regions (eFigure 2 in the Supplement). Mean (SD) frontotemporal
cortical thickness and subcortical gray matter volume were also decreased in the bvFTD-IC (2.6 [0.2]
mm and 1.3 [0.2] mm3, respectively) and bvFTD-HC (2.5 [-0.2] mm and 1.2 [0.2] mm3, respectively)
groups when compared with both the bvFTD-LC (frontotemporal cortical thickness, 2.8 [0.2] mm;
subcortical gray matter volume, 1.4 [0.2] mm3) and control (frontotemporal cortical thickness, 2.9
[0.1] mm; subcortical gray matter volume, 1.6 [0.2] mm3) groups (Table). Regarding MRPI measures,
mean (SD) midbrain volume was the sole metric reduced in bvFTD-IC (106.2 [20.4] mm3) and
bvFTD-HC (104.3 [21.1] mm3) groups compared with bvFTD-LC (125.6 [20.2] mm3) and controls
(128.0 [23.0] mm3) (Table). The mean (SD) MRPI score was increased in the bvFTD-IC (11.3 [2.7]) and
bvFTD-HC (11.6 [2.7]) groups compared with controls (9.4 [2.2]) (Table and Figure 2B).
Cerebral Measurements of Atrophy in FTLD Subgroups
ThenVAS, frontotemporal cortical thickness, and subcortical gray matter volume were similar
between FTLD subtypes (eTable 6 in the Supplement). However, participants with bvFTD and
underlying PSP or CBD and those without neuropathological confirmation who developed PSP-RS
during follow-up (n = 8) had increased values of MRPI when compared with other pathologically
proven FTLD cases (mean [SD], 14.1 [2.0] vs 11.2 [2.6]; P < .001) (Figure 2C). The diagnostic accuracy
of MRPI to differentiate between pathology-proven PSP-CBD or cases progressing to PSP-RS and
other FTLD cases was moderate (AUROC, 0.829; 95% CI, 0.739-0.919). Of note, the MRPI scores of









































































Atrophy scores and MRPI scores are compared among participants with intermediate
(bvFTD-IC), high (bvFTD-HC), and low (bvFTD-LC) confidence of frontotemporal lobar
degeneration and healthy controls. The MRPI scores are compared in participants with
bvFTD with progressive supranuclear palsy or corticobasal degeneration (PSP-CBD) or
with emergence of PSP–Richardson syndrome (PSP-RS) during follow-up and in cases
with remaining pathology-proven (other) FTLD. Atrophy scores range from 0 to 34, with
higher scores indicating more cortical atrophy. MRPI scores range from 0 to 20, with
higher scores indicating more midbrain superior peduncle atrophy. Horizontal lines
indicate medians; boxes, quartile 1 to quartile 3; whiskers, minimum to maximum values;
and dots, individual participant values.
a P < .05, adjusted for multiple comparisons (Bonferroni).
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bvFTD participants with pathology-proven PSP (n = 2) and CBD (n = 5) were similar (mean [SD], 14.5
[1.4] vs 13.5 [0.9]; P = .57).
Diagnostic Accuracy of Atrophy Scales
Figure 3A shows the diagnostic accuracy of different atrophy measurements for the differentiation
between bvFTD-HC and controls. Details on proposed cutoffs for the diagnosis of bvFTD with the
bvFTD atrophy score can be found in eTable 7 in the Supplement. The bvFTD atrophy score showed
an excellent diagnostic performance (AUROC, 0.930; 95% CI, 0.903-0.957), only outperformed by
the DFA model combining cortical thickness and subcortical volume measures (AUROC, 0.973 [95%
CI, 0.954-0.993]; P < .001). Importantly, the diagnostic accuracy of the bvFTD atrophy score was
similar to DFA models that included VAS scores (AUROC, 0.932 [95% CI, 0.906-0.959]; P = .97),
cortical thickness measures (AUROC, 0.958 [95% CI, 0.937-0.980]; P = .12), and subcortical volumes
(AUROC, 0.946 [95% CI, 0.923-0.969]; P = .26) and was superior to MRPI (AUROC, 0.743 [95% CI,
0.688-0.797]; P < .001). We obtained essentially the same results when distinguishing a combined
bvFTD-HC and bvFTD-IC group from controls (eFigure 3 in the Supplement) or when we restricted
the analyses to the subgroup of bvFTD-HC with lower clinical severity (eFigure 4 in the Supplement).
Moreover, the bvFTD atrophy score showed the second highest AUROC for the differentiation
between bvFTD-HC and bvFTD-LC (0.880; 95% CI, 0.787-0.972) (Figure 3B). In this clinical scenario,
the bvFTD atrophy score was similar to DFA models including VAS (AUROC, 0.870 [95% CI, 0.774-
0.966]; P = .64), cortical thickness measures (AUROC, 0.880 [95% CI, 0.792-0.968]; P = .99),
subcortical volumes (AUROC, 0.821 [95% CI, 0.725-0.917]; P = .06), and cortical thickness and
subcortical volumes (AUROC, 0.898 [95% CI, 0.834-0.962]; P = .62).
Estimation of Longitudinal Clinical Deterioration
Baseline bvFTD atrophy score was associated with an increased rate of clinical deterioration, as
measured with both MMSE (change per atrophy score increase per year, 1.86 [95% CI, 0.99-2.73]
points; P < .001) and CDR-SOB (change per atrophy score increase per year, 1.86 [95% CI, 0.99-2.73]
points; P < .001) (Figure 4A and eTables 8 and 9 in the Supplement). Similar performance for the
estimation of longitudinal increase in CDR-SOB was found for frontotemporal cortical thickness






















































DFA: VAS, 0.870 (0.774-0.966)
A, Area under the receiver operating characteristic curves (AUROC) for the
differentiation between participants with behavioral variant of frontotemporal dementia
with high confidence (bvFTD-HC) of frontotemporal lobar degeneration (FTLD) (n = 121)
and controls (n = 225). B, AUROC for the differentiation between participants with
bvFTD-HC and those with bvFTD with low confidence of FTLD (bvFTD-LC) (n = 19). DFA
indicates discriminant factor analyses; MRPI, Magnetic Resonance Parkinsonism Index;
and VAS, visual atrophy scales.
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(change per atrophy score increase per year, 1.45 [95% CI, 0.60-2.31] points; P = .001) and
subcortical gray matter volume (change per atrophy score point increase per year, 1.56 [95% CI,
0.55-2.56] points; P < .001). However, the MRPI was not associated with longitudinal clinical
deterioration in participants with bvFTD. Finally, we compared clinical deterioration between bvFTD
subgroups. As shown in Figure 4B, the bvFTD-LC group showed a slower clinical deterioration and
had milder atrophy than bvFTD-IC and bvFTD-HC groups (eFigure 5 in the Supplement).
Discussion
In this multicenter diagnostic/prognostic study, we found that a simple combination of 5 VAS (the
bvFTD atrophy score) had good diagnostic accuracy for the identification of bvFTD caused by FTLD.
Of note, the bvFTD atrophy score provided similar diagnostic accuracy to automated measures of
cerebral atrophy and estimated progression in bvFTD. Another novel finding of this study is that the
MRPI, a biomarker of midbrain atrophy, is increased in bvFTD with autopsy-confirmed PSP or CBD.
Current diagnostic criteria include the presence of “frontal and/or anterior temporal atrophy on
MRI” to increase the diagnostic confidence of FTLD in bvFTD,5 but some cases may present with
equivocal patterns of atrophy, and specific cutoffs for the definition of significant atrophy are lacking.
Previous work showed low sensitivity of expert radiologists for the identification of frontotemporal
atrophy,33 and other reports suggested a significant overlap in the atrophy between some cases with
bvFTD and controls.34 It could be argued that clinicians not blinded to clinical information may have
had increased sensitivity for the detection of participants with bvFTD. However, because we also
showed that cases with bvFTD-HC and bvFTD-LC had a similar clinical presentation, relying on the
subjective judgment of clinicians may also decrease the specificity of bvFTD diagnosis. Overall, our
findings support the use of VAS as reliable and reproducible tools to increase the diagnostic
confidence of FTLD in patients meeting diagnostic criteria for bvFTD at the first clinical encounter.
Notwithstanding, several other automated morphometric MRI analyses (eg, machine learning
algorithms) have also shown potential as diagnostic biomarkers in bvFTD, but further work is needed
before these methods can be recommended for clinical use.35
A key finding of our study is that measures of cortical atrophy allowed accurate estimations of
the clinical deterioration rate in bvFTD. Although previous studies have investigated the association
between atrophy and clinical deterioration in bvFTD, these included a relatively small number of
cases and did not use reproducible measures of atrophy.3 Interestingly, other studies have described
the existence of different bvFTD subtypes, including a slowly progressive variant.3,4 Our results
support that bvFTD with less cortical atrophy at diagnosis may also show a slower progression
rate.4,36,37 In other previous longitudinal studies, participants with bvFTD and less atrophy also
included bvFTD mimics (termed phenocopies) characterized by the absence of clinical deterioration
over time and alternative psychiatric diagnosis.38 Our results support the view that many of these
















































A, Estimated Clinical Dementia Rating Sum of Boxes
(CDR-SOB) values from the linear mixed-effects model
for low, intermediate, and high bvFTD visual atrophy
scale scores. B, Estimated CDR-SOB values from the
linear mixed-effects model for intermediate
(bvFTD-IC), high (bvFTD-HC), and low (bvFTD-LC)
confidence of frontotemporal lobar dementia (FTLD).
Error bars indicate 95% CI.
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bvFTD mimics could be identified at the first clinical encounter with reproducible measures of
cerebral atrophy. Additional studies are needed to investigate the role of other novel promising
neuroimaging or fluid biomarkers such as cortical mean diffusivity39 or neurofilament light chain
levels in plasma40 to increase the diagnostic accuracy of VAS and to differentiate bvFTD cases
without underlying FTLD.
Another novel finding of our study is the increased values of MRPI in bvFTD participants with
PSP or CBD on autopsy or developing PSP-RS during follow-up. Of note, diagnostic criteria for both
PSP and CBD have been updated to include a frontal/cognitive behavioral or a frontospatial variant
overlapping with the bvFTD syndrome.41,42 Our findings support the notion that bvFTD with
underlying PSP or CBD could also be diagnosed before the emergence of canonical motor symptoms
and signs supportive of PSP.43 This would be of utmost importance for the recruitment of
participants with bvFTD for clinical trials targeting 4R tauopathies. Supporting our findings, another
study10 reported that MRPI is also increased in patients who present with parkinsonism before the
emergence of supranuclear palsy or postural instability. In our study, the diagnostic accuracy of MRPI
alone for the identification of participants with PSP, CBD, or bvFTD developing PSP syndrome during
follow-up was only moderate (AUROC, 0.829). Although these findings are encouraging, this
observation is based on a relatively small number of participants, and larger pathologically proven
studies are needed to precisely determine the diagnostic value of MRPI (alone or in combination with
other biomarkers) for the differentiation of PSP and CBD pathology in bvFTD.
Limitations
This study has some limitations. First, the bvFTD-LC group was small and included participants
without autopsy confirmation. Despite this limitation, our results suggest that VAS and other
measures of atrophy could be helpful to discriminate between bvFTD-LC participants and bvFTD-HC.
This result is encouraging and deserves further investigation. Second, VAS included in this study did
not assess subcortical cortical regions that could be relevant for the diagnosis of bvFTD (ie, thalamus
or basal ganglia). Finally, we could not assess the exact precision of MRPI to detect the emergence
of PSP- and CBD-related symptoms outside of a bvFTD presentation because these participants were
not prospectively recruited in all centers.
Conclusions
This diagnostic/prognostic study found that in bvFTD, VAS increased the diagnostic certainty of
underlying FTLD, and the MRPI showed potential for the detection of participants with underlying 4R
tauopathies. These widely available measures of atrophy can also be useful to estimate longitudinal
clinical deterioration.
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